|
|
|
|
|
|
|
|
|
16.07.26 - 19:54
|
Eli Lilly Buys Psychedelics Maker Atai Beckley for $2.8 Billion to Develop DMT-Like Depression Drug (24/7 Wall St.)
|
|
|
CNBC pharma reporter Angelica Peebles broke down the biggest psychedelics deal in Big Pharma history on July 16, 2026. She framed Eli Lilly's (NYSE: LLY) acquisition of Atai Beckley as a bet on rewiring the brain rather than merely dampening symptoms. “Lilly says that it is acquiring psychedelic drug developer Atai Beckley, and Lilly will pay $6.75 ... Eli Lilly Buys Psychedelics Maker Atai Beckley for $2.8 Billion to Develop DMT-Like Depression Drug...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
16.07.26 - 14:57
|
The Big Pharma Psychedelic Buyout Spree Has Begun (ZeroHedge)
|
|
|
The Big Pharma Psychedelic Buyout Spree Has Begun
Submitted by QTR's Fringe Finance
Massive validation for psychedelics…not as drugs, but as investments could be moments away. Just months after I argued for the millionth time that psychedelic drug developers were likely to become acquisition targets as the sector gained legitimacy, it looks like the first major domino may finally be falling.
According to a Bloomberg report published moments ago, Eli Lilly is in talks to acquire AtaiBeckley, one of the leading developers of next-generation psychedelic therapies. While nothing is finalized, Bloomberg reports a deal could be announced as soon as this week, with Lilly negotiating at a premium to AtaiBeckley's roughly $2 billion market value.
If this transaction gets across the finish line, I don't think it'll be remembered as an isolated acquisition. I think it'll be remembered as the moment Big Pharma officially entered the psychedelic arms race.
I've been writing for well over a year ...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
